Radiotherapy Market 2025–2033: Size, Growth Outlook, Emerging Trends & Strategic Forecast
- Rahul Pal
- Nov 14, 2025
- 4 min read
The global Radiotherapy market was valued at USD 7.1 Billion in 2024 and is forecast to reach USD 9.9 Billion by 2033, growing at a CAGR of 3.8% during 2025-2033. The market growth is driven by rising cancer prevalence, technological advances enhancing tumor targeting accuracy, increased healthcare spending, and growing awareness of radiotherapy as a non-invasive treatment. North America dominated with over 35.8% market share in 2024.
Study Assumption Years
Base Year: 2024
Historical Year/Period: 2019-2024
Forecast Year/Period: 2025-2033
Radiotherapy Market Key Takeaways
Current Market Size: USD 7.1 Billion in 2024
CAGR: 3.8% during 2025-2033
Forecast Period: 2025-2033
North America held the largest share with over 35.8% in 2024 driven by well-established healthcare infrastructure and strong funding for cancer research.
External beam radiation therapy dominated with around 62.0% market share in 2024 due to its adaptability and precision.
Breast cancer led applications with around 28.8% share in 2024, supported by radiotherapy's role in postoperative tumor recurrence prevention.
Ambulatory and radiotherapy centers are the leading end users, favored for cost-efficiency and patient convenience.
Growing cancer incidence, especially in aging populations, and government awareness programs are notable growth drivers.
Sample Request Link:
Market Growth Factors
The increasing incidence of cancer worldwide is a primary factor driving the radiotherapy market. In 2024, approximately 2,001,140 new cancer cases are expected in the United States with 611,720 deaths. The escalating cancer burden heightens the demand for precise treatment options such as radiotherapy which targets malignant cells while sparing healthy tissues. Additionally, the aging population increases cancer risk, further fueling market needs. Government initiatives for early cancer detection and awareness campaigns promote the adoption of radiotherapy treatments.
Technological advancements significantly contribute to market growth. Innovations like image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), stereotactic body radiation therapy (SBRT), and integration of artificial intelligence are improving targeting accuracy, treatment personalization, and operational efficiency. The incorporation of AI streamlines dose planning, optimizes treatment, and predicts patient responses, broadening access and enhancing patient outcomes.
The adoption of non-invasive treatment methods and the expanding demand for personalized medicine are emerging growth enablers. Radiotherapy's non-invasive nature makes it appealing compared to surgical options. Personalized approaches customizing radiation doses based on individual patient genetic and phenotypic factors help maximize efficacy and minimize side effects. This trend is supported by a growing number of customized medications rising from 132 in 2016 to 286 in 2019 in the US, indicating a broader shift towards individualized therapies bolstering radiotherapy adoption.
Market Segmentation
By Type:
External Beam Radiation Therapy: The most widely used type due to high precision targeting of tumors with minimal impact on surrounding tissues.
Intensity-Modulated Radiation Therapy (IMRT)
Image-Guided Radiation Therapy (IGRT)
Tomotherapy
Stereotactic Radiosurgery
Stereotactic Body Radiation Therapy
Proton Therapy
3D Conformal Radiotherapy (3D CRT)
Volumetric Modulated Arc Therapy (VMAT)
Internal Radiation Therapy/Brachytherapy
Systemic Radiation Therapy
By Application:
Skin and Lip Cancer
Head and Neck Cancer
Breast Cancer: The leading application segment due to its critical role as a postoperative therapy to prevent tumor recurrence.
Prostate Cancer
Cervical Cancer
Lung Cancer
Others
By End User:
Hospitals
Cancer Research Institutes
Ambulatory and Radiotherapy Centers: These centers are preferred for outpatient care providing cost-effective, specialized treatment avoiding hospital stays.
By Region:
Asia Pacific
Europe
North America
Latin America
Middle East and Africa
Regional Insights
North America dominates the radiotherapy market with over 35.8% share in 2024. The region benefits from advanced healthcare infrastructure, robust funding for cancer research, leading cancer research facilities, early cancer screening programs, and significant investment in advanced medical equipment. The U.S. accounts for over 85.00% of North America's market, driven by high cancer incidence and increased healthcare expenditure, which is projected to rise from USD 4.8 trillion in 2023 to USD 7.7 trillion by 2032.
Recent Developments & News
October 2024: Eckert & Ziegler SE entered a global clinical supply agreement with GlyTherix Ltd to provide Lutetium-177 chloride for clinical trials targeting solid tumors.
August 2024: Accuray Incorporated received CE Mark approval for the Accuray Helix, a CT-guided helical radiotherapy system targeting emerging markets with limited advanced cancer care.
August 2024: Elekta received a USD 64 Million order from Hospital Angeles Health System in Mexico for advanced linear accelerators and the Elekta Esprit Gamma Knife.
September 2023: Siemens Healthineers acquired Aspekt to enhance radiation oncology services.
May 2023: General Electric Company launched new radiotherapy instruments including auto segmentation and an updated MR radiation therapy suite.
Key Players
Accuray Incorporated
Becton Dickinson and Company
Eckert & Ziegler
Elekta AB (publ)
General Electric Company
Hitachi Ltd
Ion Beam Applications
Isoray Inc.
Mevion Medical Systems Inc.
Nordion Inc. (Sotera Health)
Siemens Healthineers AG (Siemens AG)
Customization Note
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
Comments